��������

Ian McGowan currently serves as Chief Medical Officer at Synklino since October 2024. Prior to this role, Ian held the position of Chief Medical Officer and Chief Scientific Officer at Orion Biotechnology from September 2017 to September 2024, and before that, was Chief Medical Officer at AELIX Therapeutics from March 2017 to August 2018. Ian's academic career includes a tenure as Professor of Medicine at the University of Pittsburgh, where contributions included co-leading the NIH-funded Microbicide Trials Network. Ian also held significant roles at the University of California, Los Angeles, Agennix, Intrabiotics, Gilead Sciences, and GlaxoWellcome, focusing on HIV research and clinical development. Ian earned a Ph.D. from the University of Oxford, an MD from the Liverpool School of Tropical Medicine, and an MB ChB from the University of Liverpool, alongside a Fellowship of the Royal College of Physicians (FRCP).